Abstract

Sepsis is a major cause of death in intensive care units worldwide. The acute phase of sepsis is often accompanied by sepsis-associated encephalopathy, which is highly associated with increased mortality. Moreover, in the chronic phase, more than 50% of surviving patients suffer from severe and long-term cognitive deficits compromising their daily quality of life and placing an immense burden on primary caregivers. Due to a growing number of sepsis survivors, these long-lasting deficits are increasingly relevant. Despite the high incidence and clinical relevance, the pathomechanisms of acute and chronic stages in sepsis-associated encephalopathy are only incompletely understood, and no specific therapeutic options are yet available. Here, we review the emergence of sepsis-associated encephalopathy from initial clinical presentation to long-term cognitive impairment in sepsis survivors and summarize pathomechanisms potentially contributing to the development of sepsis-associated encephalopathy.

Highlights

  • Sepsis is a life-threatening and multi-factorial disease with continuously increasing incidence over recent decades from 300 to 1000 sepsis cases per 100,000 people per year in the United States

  • Even though this study was not designed to investigate the effect of rivastigmine on Sepsis-associated encephalopathy (SAE) patients, these results suggest that cholinesterase inhibitors do not have a beneficial effect in sepsis patients

  • It should be noted that existence of cerebralabscesses should rather be regarded as infectious encephalitis than as SAE

Read more

Summary

Introduction

Sepsis is a life-threatening and multi-factorial disease with continuously increasing incidence over recent decades from 300 to 1000 sepsis cases per 100,000 people per year in the United States. The overall global incidence is approximately 31 million sepsis cases per year [1,2]. Sepsis-associated encephalopathy (SAE) is one of the most common complications during the acute phase and in later stages after surviving sepsis. It is defined by a diffuse cerebral dysfunction due to the dysregulated host response and absence of a direct central nervous system (CNS) infection. SAE symptoms may already be present before sepsis criteria are fulfilled. From a clinical point of view, the disease course of SAE can be sub-divided into an acute and a chronic phase

Acute Phase of SAE—Delirium
Chronic Phase of SAE—Dementia
Epidemiology
Impairment of Blood–Brain Barrier and Neuroinflammation
Dysregulated Neurotransmitter
Neuropathological Findings
Diagnostic Procedures
Cerebral Imaging
Laboratory Testing—Cerebrospinal Fluid
Laboratory Testing—Blood
Screening Tests for Delirium in Acute SAE
Pharmacological Treatment
Non-Pharmacological Treatment
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call